Washed microbiota transplantation promotes homing of group 3 innate lymphoid cells to the liver via the CXCL16/CXCR6 axis: a potential treatment for metabolic-associated fatty liver disease

• Published in: Gut microbes 2024-12, Vol.16 (1), p.2372881
• Main Authors: Zhong, Hao-Jie, Zhuang, Yu-Pei, Xie, Xinqiang, Song, Jia-Yin, Wang, Si-Qi, Wu, Lei, Zhan, Yong-Qiang, Wu, Qingping, He, Xing-Xiang
• Format: Article
• Language: English
• Subjects: Animals; Chemokine CXCL16 - metabolism; Chemokine receptor; Fatty Liver - metabolism; Fatty Liver - microbiology; Fatty Liver - therapy; Fecal Microbiota Transplantation; Female; Gastrointestinal Microbiome; group 3 innate lymphoid cells; gut microbiota; Humans; Immunity, Innate; Interleukin-22; Interleukins - metabolism; Liver - metabolism; Liver - microbiology; Lymphocytes - immunology; Lymphocytes - metabolism; Male; metabolic-associated fatty liver disease; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease - immunology; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - microbiology; Non-alcoholic Fatty Liver Disease - therapy; Receptors, CXCR6 - metabolism; Research Paper
• ISSN: 1949-0976; 1949-0984; 1949-0984
• DOI: 10.1080/19490976.2024.2372881

Despite the observed decrease in liver fat associated with metabolic-associated fatty liver disease (MAFLD) in mice following fecal microbiota transplantation, the clinical effects and underlying mechanisms of washed microbiota transplantation (WMT), a refined method of fecal microbiota transplantation, for the treatment of MAFLD remain unclear. In this study, both patients and mice with MAFLD exhibit an altered gut microbiota composition. WMT increases the levels of beneficial bacteria, decreases the abundance of pathogenic bacteria, and reduces hepatic steatosis in MAFLD-affected patients and mice. Downregulation of the liver-homing chemokine receptor CXCR6 on ILC3s results in an atypical distribution of ILC3s in patients and mice with MAFLD, characterized by a significant reduction in ILC3s in the liver and an increase in ILC3s outside the liver. Moreover, disease severity is negatively correlated with the proportion of hepatic ILC3s. These hepatic ILC3s demonstrate a mitigating effect on hepatic steatosis through the release of IL-22. Mechanistically, WMT upregulates CXCR6 expression on ILC3s, thereby facilitating their migration to the liver of MAFLD mice via the CXCL16/CXCR6 axis, ultimately contributing to the amelioration of MAFLD. Overall, these findings highlight that WMT and targeting of liver-homing ILC3s could be promising strategies for the treatment of MAFLD.